Jens Eckstein
Directeur/Bestuurslid bij IMUGENE LIMITED
Vermogen: 1 M $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Nick Ede | M | - | 11 jaar | |
Leslie Chong | F | - | 9 jaar | |
Paul Hopper | M | 68 | 12 jaar | |
Allison Hulme | M | 61 |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | - |
Alexandra Bause | M | - |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | - |
Samir Ounzain | M | - |
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | - |
Michael Tonroe | M | 57 | 2 jaar | |
Marianne Mertens | M | - |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg.
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | - |
Peter de Keizer | M | - |
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | 6 jaar |
Ursula Wiedermann | F | - | - | |
Ole Mensching | M | - |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | 8 jaar |
Nils Regge | M | 42 |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | 8 jaar |
Daniel Blessing | M | - |
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | - |
Jim Broderick | M | 55 |
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | - |
Joseph Woodard | M | 58 | 1 jaar | |
Brian Thomas | M | 55 |
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | 2 jaar |
Ursula McCurry | F | - | - | |
Bradley Glover | M | 55 | 1 jaar | |
Steven Leunert | M | - |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | - |
Victor Bustos | M | - |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | 6 jaar |
Diogo Feleciano | M | - |
Apollo Ventures Holding GmbH
Apollo Ventures Holding GmbH Investment ManagersFinance Apollo Ventures Holding GmbH (Apollo Health Ventures) is an Independent Venture Capital firm founded in 2016 by Nils Regge and Alexandra Bause. The firm is headquartered in Hamburg. | 5 jaar |
Sharon Yavrom | M | - | 2 jaar | |
Lesley Russell | M | 63 | 5 jaar | |
Richard Gaster | M | 40 |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | 5 jaar |
Anthony Good | M | - | - | |
Benjamin Kreitman | M | - |
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | 4 jaar |
Sarah Bhagat | M | 38 |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | 5 jaar |
Michael Teifel | M | - |
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | - |
Michael Powell | M | 69 |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | - |
Adam Walker | M | 57 |
Action Potential Venture Capital
Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | 9 jaar |
Monil Shah | M | - | 3 jaar | |
Jakob Dupont | M | 58 | 2 jaar | |
Juan-Pablo Mas | M | - |
Action Potential Venture Capital
Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | 10 jaar |
Angelos Stergiou | M | 48 |
Cleara Biotech BV
Cleara Biotech BV Pharmaceuticals: MajorHealth Technology Cleara Biotech BV operates as a biopharmaceutical company. It specializes in identification and specific elimination of subtypes of senescent cells with targeting age related diseases and counteracting therapy resistance in late stage cancer. The company was founded by Peter de Keizer, Marco Demaria, Tobias Madl and is headquartered in Utrecht, the Netherlands. | 2 jaar |
Kimberlee Drapkin | F | 55 | 1 jaar | |
Stephen Hoffman | M | 70 |
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | - |
John Byon | M | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Axel Hoos | M | 54 | 8 jaar | |
Phillip Hains | M | 64 | 11 jaar | |
Charles Walker | M | 53 | 9 jaar | |
Paul Blackburn | M | 70 |
Action Potential Venture Capital
Action Potential Venture Capital Investment ManagersFinance Action Potential Venture Capital (Action Potential Venture) is a venture capital subsidiary of GlaxoSmithKline Plc founded in 2013. The firm is headquartered in London, United Kingdom. | 3 jaar |
Justyn Stedwell | M | - | 9 jaar | |
Mark T. Marino | M | - | 2 jaar | |
Rita Laeufle | M | - | 2 jaar | |
Nathan Jong | M | - | 2 jaar | |
Giovanni Selvaggi | M | - | 1 jaar | |
Steven Cha | M | - | - | |
Ron Weitzman | M | - | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Australië | 25 | 52.08% |
Verenigde Staten | 9 | 18.75% |
Duitsland | 7 | 14.58% |
Nederland | 5 | 10.42% |
Zwitserland | 4 | 8.33% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jens Eckstein
- Persoonlijk netwerk